Date published: 2025-12-23

1-800-457-3801

SCBT Portrait Logo
Seach Input

myo-Inositol Trispyrophosphate Hexasodium Salt (CAS 23103-35-7)

0.0(0)
Write a reviewAsk a question

Alternate Names:
ITTP Hexasodium Salt
Application:
myo-Inositol Trispyrophosphate Hexasodium Salt is a membrane-permeant allosteric effector of hemoglobin
CAS Number:
23103-35-7
Molecular Weight:
737.88
Molecular Formula:
C6H6O21P66Na
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

myo-Inositol Trispyrophosphate Hexasodium Salt is a novel membrane-permeant allosteric effector of hemoglobin (Hb), enhances the regulated oxygen release capacity of red blood cells, thus counteracting the effects of hypoxia in diseases such as cancer and cardiovascular ailments. myo-Inositol Trispyrophosphate Hexasodium Salt is a compound consisting of a hexasodium salt of ITTP (1,3,5-triisopropyl-2,4,6-trioxane-1,3,5-triyl triacetate), a polyether compound. Initially synthesized in the 1970s, it has gained significant prominence as a versatile reagent in the field of chemistry. Its applications span diverse areas, including the synthesis of novel compounds like polyethers, polyesters, organic and inorganic compounds, peptide and peptoid molecules, as well as polymers such as polyurethanes, polyamides, and polycarbonates.


myo-Inositol Trispyrophosphate Hexasodium Salt (CAS 23103-35-7) References

  1. Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, myo-inositol trispyrophosphate.  |  Biolo, A., et al. 2009. Proc Natl Acad Sci U S A. 106: 1926-9. PMID: 19204295
  2. myo-Inositol trispyrophosphate: a novel allosteric effector of hemoglobin with high permeation selectivity across the red blood cell plasma membrane.  |  Duarte, CD., et al. 2010. Chembiochem. 11: 2543-8. PMID: 21086482
  3. Polyphosphates and pyrophosphates of hexopyranoses as allosteric effectors of human hemoglobin: synthesis, molecular recognition, and effect on oxygen release.  |  Fylaktakidou, KC., et al. 2011. ChemMedChem. 6: 153-68. PMID: 21108295
  4. Diabetic nephropathy: are there new and potentially promising therapies targeting oxygen biology?  |  Miyata, T., et al. 2013. Kidney Int. 84: 693-702. PMID: 23486514
  5. New potential treatment for cardiovascular disease through modulation of hemoglobin oxygen binding curve: Myo-inositol trispyrophosphate (ITPP), from cancer to cardiovascular disease.  |  Oknińska, M., et al. 2022. Biomed Pharmacother. 154: 113544. PMID: 35988421

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

myo-Inositol Trispyrophosphate Hexasodium Salt, 10 mg

sc-362062
10 mg
$449.00